Prognostic significance of nonsustained XXXX after revascularization.

@entity1 @entity308 @entity1165 @entity944 @entity737 @entity2224 @entity453
INTRODUCTION: Two randomized trials (Multicenter Automatic Defibrillator Implantation Trial [MADIT] and Multicenter Unsustained Tachycardia Trial [MUSTT]) suggest that @entity737 ( @entity737 ) placement is associated with improved survival in @entity1 with @entity453 , @entity308 , and nonsustained @entity1165 ( @entity1165 ) who also have inducible sustained @entity1165 . However, neither study directly addresses the management of such @entity1 who develop nonsustained @entity1165 early after revascularization. METHODS AND RESULTS: We evaluated 109 consecutive @entity1 who underwent electrophysiologic testing to evaluate nonsustained @entity1165 , which occurred 5 +/- 4 days following revascularization. Sustained monomorphic @entity1165 was inducible in 46 (42%) @entity1 ; these @entity1 received an @entity737 . The remaining 63 (58%) noninducible @entity1 received neither antiarrhythmic drug therapy nor an @entity737 . During 27 +/- 12 months of follow-up, 15 (33%) of 45 @entity1 with an implanted @entity737 received at least one appropriate therapy from the device and 26 (24%) of the 109 study @entity1 died. The 1- and 2-year freedom from @entity2224 or @entity944 in noninducible @entity1 (97% and 93%) was significantly greater than that of inducible @entity1 (84% and 71%; P = 0.001). However, no difference was observed in total mortality. CONCLUSION: @entity1 with nonsustained @entity1165 during the early postrevascularization period who have inducible @entity1165 have a high incidence of arrhythmic events. Although this study was not designed to assess the impact of @entity737 placement on the total mortality of inducible @entity1 , the finding that one third of these @entity1 received appropriate @entity737 therapy suggests that the device may have a protective effect in these @entity1 .
